Drugs / ANG1005
ANG1005
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00539344 | Oct 2007 → Mar 2010 | malignant glioma | Angiochem Inc | Completed | No outcome recorded |
| Phase 1 | NCT00539383 | Oct 2007 → Mar 2010 | neoplasm | Angiochem Inc | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT02048059 | Apr 2014 → Mar 2016 | breast cancer, metastatic malignant neoplasm in the brain | Angiochem Inc | Completed | No outcome recorded |
| Phase 2 | NCT01967810 | Oct 2013 → Feb 2016 | brain cancer, glioblastoma | Angiochem Inc | Completed | No outcome recorded |
| Phase 2 | NCT01679743 | Aug 2012 → Aug 2014 | breast cancer, lung cancer | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT01497665 | Nov 2011 → Jan 2013 | non-small cell lung carcinoma | Angiochem Inc | Terminated | No outcome recorded |
| Phase 2 | NCT01480583 | Oct 2011 → Jun 2015 | breast cancer, metastatic malignant neoplasm in the brain | Angiochem Inc | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03613181 | Dec 2023 → Dec 2024 | Her2-receptor negative breast cancer, malignant leptomeningeal tumor, metastatic malignant neoplasm in the brain, neoplastic meningitis | Angiochem Inc | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02755987 | — | anaplastic astrocytoma, anaplastic oligodendroglioma, breast cancer, neoplastic meningitis | Angiochem Inc | No longer available | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANG1005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01967810 ↗ |
| Known as | GRN1005 | “GRN1005 will be administered at a dose of 550 mg/m2 as an IV infusion at a rate of 8.0 - 8.5 mL/minute on Day 1 of 21-day cycle ( 3 days) and a second dose will be given on the...” NCT01679743 ↗ |
| Known as | Paclitaxel trevatida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1089636 ↗ |
| Known as | Paclitaxel trevatide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1089636 ↗ |
| Modality | Peptide | “GRN1005 is a peptide-drug conjugate” PMID 23349317 ↗ Jan 2013 |
| Route | Intravenous | “ANG1005 will be given by IV infusion once every 21 days” NCT00539344 ↗ |
| Target | LRP1 | “by targeting the low-density lipoprotein receptor-related protein-1” PMID 23349317 ↗ Jan 2013 |